Thalys Medical Technology Group Inc. Class A

Thalys Medical Technology Group Inc. Class A

SSSE:603716
14.28
CNY
-0.53
(-3.58%)
-0.84EPS
3.75BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Thalys Medical Technology Group Inc. Class A carries a market capitalization of 3.75B, placing it among publicly traded companies globally. Its enterprise value stands at 3.84B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.75B
Enterprise Value3.84B

Share Statistics

As of September 30, 2026, Thalys Medical Technology Group Inc. Class A has 225.79M shares outstanding.

Shares Outstanding225.79M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 5.08, and the price-to-book ratio stands at 3.46.

PS Ratio5.08
PB Ratio3.46
P/TBV Ratio3.61

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 5.41 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.84B versus a market cap of 3.75B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales5.41

Financial Position

As of September 30, 2026, Thalys Medical Technology Group Inc. Class A maintains a current ratio of 1.97, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.80, indicating elevated leverage, while an interest coverage ratio of -20.81 demonstrates limited ability to service its debt obligations.

Current Ratio1.97
Quick Ratio0.16
Debt / Equity22.80
Debt / EBITDA-1.75
Interest Coverage-20.81

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Thalys Medical Technology Group Inc. Class A posted a negative return on equity (ROE) of -17.96, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.44, reflecting losses generated across the asset base. The company generates approximately 678,770.20 in revenue per employee across its workforce of 1,045.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.50 indicates how many times Thalys Medical Technology Group Inc. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-17.96
Return on Assets (ROA)-9.44
Revenue Per Employee678,770.20
Employee Count1,045.00
Inventory Turnover2.50

Taxes

CNY

Over the twelve months ended September 30, 2026, Thalys Medical Technology Group Inc. Class A recorded 44.20M in income tax expense. The company reported a pretax loss of -138.21M and -176.05M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax44.20M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Thalys Medical Technology Group Inc. Class A's stock has declined approximately 36.56% over the past 52 weeks. The 50-day moving average sits at 15.99, while the 200-day moving average is 18.53.

52-Week Price Change-36.56%
50-Day Moving Average15.99
200-Day Moving Average18.53

Income Statement

CNY

Over the twelve months ended September 30, 2026, Thalys Medical Technology Group Inc. Class A generated 709.31M in revenue and converted that into -176.05M in net income, yielding earnings per share of -0.84. EBITDA reached -132.24M, while operating income came in at -84.69M.

Revenue709.31M
Gross Profit169.51M
Operating Income-84.69M
Pretax Income-138.21M
Net Income-176.05M
EBITDA-132.24M
EBIT-132.24M
Earnings Per Share (EPS)-0.84

Balance Sheet

CNY

As of September 30, 2026, Thalys Medical Technology Group Inc. Class A holds 78.81M in cash and equivalents against 231.99M in total debt, resulting in a net debt position of 134.50M. Total book value stands at 1.08B, with working capital of 472.78M providing operational flexibility.

Cash & Cash Equivalents78.81M
Total Debt231.99M
Net Debt134.50M
Equity (Book Value)1.08B
Book Value Per Share4.80
Working Capital472.78M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-2.24M

Margins

Over the twelve months ended September 30, 2026, Thalys Medical Technology Group Inc. Class A posted a gross margin of 23.90, reflecting its pricing power and cost economics. The operating margin of -11.94 and net profit margin of -24.82 provide insight into operational efficiency.

Gross Margin23.90
Operating Margin-11.94
Pretax Margin-19.48
Profit Margin-24.82
EBITDA Margin-18.64

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Thalys Medical Technology Group Inc. Class A paid dividends of 0.01 per share. The dividend payout ratio of -1.00 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.60, meaning Thalys Medical Technology Group Inc. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.01
Payout Ratio-1.00
Shareholder Yield-0.60

Stock Splits

Thalys Medical Technology Group Inc. Class A's most recent stock split took place on April 25, 2018 with a 2:5 split ratio.

Last Split Date4/25/2018
Split Ratio2:5

Scores

As of September 30, 2026, Thalys Medical Technology Group Inc. Class A has an Altman Z-Score of 4.87, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.87